Natera transplant data show no edge over CareDx, says Piper Jaffray

After Natera (NTRA) published its full cell-free DNA data for kidney rejection in the Journal of Clinical Medicine, Piper Jaffray analyst William Quirk reiterates an Overweight rating on CareDx (CDNA). The publication Natera does not have any advantage over CareDx largely due to the fact that creatinine, which is a non-specific marker for transplant rejection, showed statistical significance in identifying injury, Quirk tells investors in a research note. The analyst thinks “this important element” in the Natera data will require additional clinical work before the test could be considered competitive with CareDx’s. He continues to believe CareDx’s “first mover advantage is significant.”

https://thefly.com/landingPageNews.php?id=2842716